布隆迪北部边境地区疟疾耐药监测(2023—2024年)
蒿甲醚/苯芴醇治疗后仅首剂直接观察,第3天4.5%患儿仍有疟原虫血症,未检出pfkelch13突变,但抗叶酸和4-氨基喹啉耐药标志广泛流行,提示需加强疗效监测和区域分子监测。
要点
- 第3天疟原虫血症率为4.5%,提示寄生虫清除延迟。
- 未检出pfkelch13突变(ART-R验证或候选标志)。
- dhfr三突变体N51I/C59R/S108N近固定(92%),pfcrt CVIET占84%。
核心结论
- 虽未检出ART-R标志,但寄生虫清除延迟及多重耐药单倍型近固定构成警告,需紧急加强疗效监测和区域分子监测。
研究设计与样本
- 蒿甲醚/苯芴醇治疗仅首剂直接观察。
主要发现
- 治疗后第3天4.5%患儿仍有疟原虫血症。
- 未检出pfkelch13突变(ART-R验证或候选标志)。
- dhfr三突变体N51I/C59R/S108N近固定(92%),dhps双突变和三突变常见(41%和47%)。
- pfcrt CVIET(与氯喹和阿莫地喹耐药相关)占优势(84%)。
- 第3天阳性率和单倍型频率存在地理差异。
关键数值与推荐
- 第3天疟原虫血症率4.5%。
- dhfr三突变体N51I/C59R/S108N频率92%。
- dhps双突变和三突变频率分别为41%和47%。
- pfcrt CVIET频率84%。
临床怎么用
- 对布隆迪北部边境地区疟疾患者,应关注蒿甲醚/苯芴醇治疗后第3天寄生虫清除情况。
- 需加强抗疟药疗效监测和区域分子监测,防止耐药恶性疟在布隆迪扎根。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To evaluated artemisinin partial resistance (ART-R) in malaria in Burundi, during December 2023-June 2024, we studied 423 children <5 years of age with uncomplicated Plasmodium falciparum malaria in 8 health facilities in the northern part of the country. After artemether/lumefantrine treatment with only the first dose directly observed, 4.5% remained parasitemic on day 3. No pfkelch13 mutations, validated or candidate markers of ART-R, were detected. However, markers of antifolate and 4-aminoquinoline resistance were widespread: the dhfr triple mutant N51I/C59R/S108N was nearly fixed (92%), dhps double and triple mutants were common (41% and 47%), and pfcrt CVIET, associated with chloroquine and amodiaquine resistance, predominated (84%). Geographic differences occurred in day-3 positivity and haplotype frequencies. Although ART-R markers were absent, delayed parasite clearance and near fixation of multidrug-resistant haplotypes serve as a warning. Strengthened efficacy monitoring and regional molecular surveillance are urgently needed to prevent drug-resistant P. falciparum from becoming established in Burundi.
引用
- Niyomwungere D, Sinarinzi P, Caspar E, et al. Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023-2024. Emerg Infect Dis. 2026. PMID: 41927306. doi:10.3201/eid3204.251711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。